Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601 | 0.85 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2GAACYP1A2 | |
| SCHEMBL10775 | 0.85 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2GAACYP1A2 | |
| SCHEMBL2498564 | 0.83 | CYP3A4 (0.41) | GAACYP1A2CYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL16183174 | 0.82 | CYP2C19 (0.50) | MEN1KMT2ASMN1; SMN2GAACYP1A2 | |
| SCHEMBL30673452 | 0.82 | CYP2C19 (0.50) | MEN1KMT2ASMN1; SMN2GAACYP1A2 | |
| SCHEMBL6655873 | 0.81 | SMN1; SMN2 (0.38) | MEN1KMT2ASMN1; SMN2GAACYP1A2 | |
| SCHEMBL22165427 | 0.81 | TSHR (0.41) | SMN1; SMN2GAACYP3A4CYP2C19ALDH1A1 | |
| SCHEMBL2501365 | 0.81 | LMNA (0.46) | SMN1; SMN2CYP1A2MAPTMAPK1LMNA | |
| SCHEMBL22111154 | 0.81 | GAA (0.43) | MEN1KMT2ASMN1; SMN2GAATP53BP1 | |
| SCHEMBL16081706 | 0.81 | PARP1 (0.44) | MEN1KMT2ASMN1; SMN2GAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019016269-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2019-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | MEN1 3794/4885KMT2A 3371/4885SMN1; SMN2 1439/4885 |
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | MEN1 4135/4885KMT2A 1276/4885SMN1; SMN2 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.